Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL)

Core Insights - Personalis, Inc. (NASDAQ:PSNL) is recognized as one of the 12 best genomics stocks to invest in [1] - Morgan Stanley has initiated coverage of Personalis with an Equal Weight rating and a price target increase from $9 to $11, citing upcoming catalysts in 2026 and favorable sector dynamics [2] Financial Performance - The company has revised its full-year 2025 sales forecast down from a range of $70 million to $80 million to a new range of $68 million to $73 million [3] - Revenue projections from pharmaceutical testing and services have been lowered from $52 million to $58 million to a new range of $50 million to $54 million [3] - In contrast, revenue from population sequencing and enterprise clients has been increased to a range of $16.5 million to $17 million, up from previous projections of $15 million to $16 million [4] - Clinical test reimbursed revenue has decreased significantly from a range of $3 million to $6 million to a new range of $1.5 million to $2 million [4] - The company maintains a gross margin estimate of 22% to 24% and anticipates a net loss of approximately $85 million, with cash consumption around $75 million [4] Business Overview - Personalis, Inc. specializes in genomic sequencing and analytics technologies aimed at developing personalized cancer vaccines and next-generation cancer immunotherapies [5]